Drug Trial Radar · NCT00887978
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
310
Actual
Start
Jun 2009
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits will occur at 4 week intervals for 16 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Patients who complete all assessments for 16-weeks will also be eligible to enter an open-label, extension phase study (FREEDOM - EXT).
Conditions
- Pulmonary Hypertension
Interventions
UT-15C SRDrug
treprostinil diolamine sustained release tablets
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-minute Walk Distance (6MWD)Time frame: Baseline and 16 weeks
Locations
62 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama-Birmingham
Birmingham, Alabama
Arizona Pulmonary Specialist, LTD
Phoenix, Arizona
University of California, San Francisco-Fresno
Fresno, California
UCSD Medical Center
La Jolla, California
West Los Angeles VA Healthcare Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
Harbor-UCLA Medical Center
Torrance, California
University of Colorado Health Science Center
Aurora, Colorado
University of Florida-Jacksonville
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
Emory University School of Medicine
Atlanta, Georgia
University of Chicago Hospitals
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Kansas University Medical Center
Kansas City, Kansas
Kentuckiana Pulmonary Associates
Louisville, Kentucky
Maine Medical Center
Portland, Maine
Tufts Medical Center
Boston, Massachusetts
Pulmonary Critical Care Medicine, Brigham and Women's Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Washington University Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Newark Beth Israel Medical Center
Newark, New Jersey
Winthrop University Hospital
Mineola, New York
Columbia University Presbyterian Medical Center
New York, New York
Mary M Parkes Center for Asthma, Allergy and Pulmonary Care
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Lindner Center
Cincinnati, Ohio
University of Cincinnati
Cincinnati, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
Ohio State University
Columbus, Ohio
The University of Toledo
Toledo, Ohio
Legacy Pulmonary Northwest
Portland, Oregon
OHSU
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
UT Southwestern
Dallas, Texas
The University of Texas Health Science Center at Houston
Houston, Texas
Intermountain Medical Center
Murray, Utah
Inova Transplant Center
Falls Church, Virginia
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.